The alternative proangiogenic factors CXCL2 and IL8, which act through CXCR2 or CXCR1, seem to be promising therapeutic targets due to their expression in glioma cell lines and mouse models [12,13,14,15]. This evidence concerns the gene CXCL2 and central nervous system cancer.